SARMs Charts: Half-Lives, Research and Suppression Compared
Charts from the Sarmguide database: half-lives, research stage, human studies, testosterone suppression and study doses. Free to embed with a credit link.
Key takeaways
Five charts from the database: half-life, research stage, human studies, suppression and study doses.
Each chart names its source and the date of the last data review.
Free to embed (iframe or SVG) with the credit link kept in place.
Compounds without human data are left out rather than estimated.
Five charts drawn from the Sarmguide compound database: half-lives, how far each compound got in clinical research, how many human studies exist, how much testosterone fell in studies, and the doses human studies used. Each chart names its source, lists every value for screen readers and can be embedded on your own site for free with a credit link.
Half-lives compared
Elimination half-life in people, where measured (log scale; bars show the reported range). Values from different studies and routes are not directly comparable.
Half-life is the time it takes for blood levels to fall by half (NCI); after about five half-lives roughly 3% is left (StatPearls). The scale is logarithmic because the values run from minutes (tesamorelin) to weeks (the main tamoxifen metabolite). Compounds without a published human half-life are left out: MK-677, cardarine, the SARMs that never reached human trials (such as YK-11 and S-23) and most research peptides. For MK-677, an FDA review in 2024 found no detailed human pharmacokinetic data (FDA 2024).
How far each compound got in clinical research
Furthest stage of human clinical trials reached (Preclinical = animal or cell studies only; Approved = approved as a medicine somewhere).
“Approved” means approved as a medicine somewhere, usually for another use (tamoxifen and anastrozole for breast cancer, tesamorelin for abdominal fat in HIV). No SARM is approved. “Preclinical” means animal or cell studies only.
Human studies per compound
Human studies per compound, as counted in the database: human treatment studies we found and checked (animal, cell and anti-doping excretion studies not counted); † approved or late-stage drugs: PubMed records typed Clinical Trial or RCT (searched 30 Oct 2026). Log scale: each grid line is ten times the one before.
These are the human studies we found and checked, not every study ever run. Approved drugs such as tamoxifen and clomiphene have hundreds or thousands; most SARMs and peptides have a handful. When the gap is that large, the chart switches to a log scale so the small counts stay visible.
Testosterone suppression reported in studies
Sarmguide score from 0 (none found) to 3 (marked suppression), based on the cited studies of each compound. "(animal)" means the score rests on animal data because suppression was not measured in men; compounds with no data at all are left out.
A Sarmguide score from 0 (none reported) to 3 (marked), based on the cited studies. The evidence behind a score differs: for LGD-4033 and ostarine it comes from human trials, for RAD-140 from monkeys, because no trial has measured testosterone in men taking it. Compounds never tested for this are not shown. See the side effects guide for the numbers behind each score.
Doses used in human studies: ostarine as an example
What the published studies used and found. These are research doses reported in the studies, not recommendations. Dots mark each dose a study tested (per-kg doses are listed in the table only).
Dose studied
Who took part
Duration
What the study found
Source
0.1, 0.3, 1 or 3 mg/day
Healthy men over 60 and postmenopausal women (n=120)
86 days
Randomized, double-blind, placebo-controlled Phase 2 On 3 mg, lean mass rose 1.3 kg more than placebo; 1 mg gave +0.7 kg (not significant). Physical function and insulin resistance improved on 3 mg. HDL fell 17% (1 mg) and 27% (3 mg).
Men over 45 and postmenopausal women with cancer and at least 2% weight loss (n=159)
Up to 113 days
Randomized, double-blind, placebo-controlled Phase 2 Median lean mass rose 1.5 kg (1 mg) and 1.0 kg (3 mg) from baseline; no change on placebo (100 people in the efficacy analysis). Serious adverse events were not judged drug-related.
Healthy young men and elderly men with truncal obesity (Phase 1)
14 days
Double-blind, placebo-controlled multiple-ascending-dose Phase 1 (G100402) Terminal half-life 14–21 hours. SHBG and total testosterone fell with dose; free testosterone did not change in a clinically significant way. A dose-dependent rise in ALT was the most common side effect.
Patients with non-small cell lung cancer starting platinum + taxane chemotherapy (POWER 1) (n=321)
147 days (primary analysis at day 84)
Randomized, double-blind, placebo-controlled Phase 3 Did not meet its co-primary endpoints. Stair-climb responders: 29.4% vs 24.2% on placebo. No lean-mass loss: 41.9% vs 30.4%.
Patients with non-small cell lung cancer starting platinum + non-taxane chemotherapy (POWER 2) (n=330)
147 days (primary analysis at day 84)
Randomized, double-blind, placebo-controlled Phase 3 Did not meet its co-primary endpoints. Stair-climb responders: 19.5% vs 24.8% on placebo. No lean-mass loss: 46.5% vs 37.9%.
Postmenopausal women with AR+/ER+/HER2- advanced breast cancer (n=136)
Until progression (median follow-up 7.5 months)
Randomized, open-label Phase 2 (two doses, no placebo) Clinical benefit at 24 weeks in 32% (9 mg) and 29% (18 mg). Grade 3/4 drug-related side effects in 8% and 16%, most often raised liver enzymes.
Adults over 60 with overweight or obesity on semaglutide (n=168)
16 weeks
Randomized, double-blind, placebo-controlled Phase 2b (QUALITY) Company topline result: 71% less lean-mass loss than semaglutide alone (p=0.002) and 27% more fat loss (p=0.096). Total weight loss was similar. Not yet published in a journal.
Every compound’s fact sheet has its own dose chart with the full table of studies. These are research doses reported in the studies, not recommendations.
Embed a chart on your site
Under each chart, “Embed this chart” gives you two snippets: an interactive version (iframe) and a plain image (SVG). Both are free to use as long as the credit link to Sarmguide stays with the chart. Charts update themselves when the database changes, and the source line shows the date of the last review.
To embed a chart for one compound, open that compound’s fact sheet and use the embed box there, or add ?compound= to the chart address, for example /embed/chart/half-life/?compound=rad-140. Need a chart we do not have? Tell us.
Frequently asked questions
Can I use these charts on my site?
Yes, with the credit linkEvidence: Limited
Use the "Embed this chart" box under any chart (iframe or SVG). It is free as long as the credit link to Sarmguide stays with the chart.
Charts are drawn from the database, so they change as soon as a compound record is updated. The source line under each chart shows the date of the last review.
No human plasma half-life has been published, and an FDA review in 2024 found no detailed human pharmacokinetic data. Figures quoted online come from sellers and blogs, so it is left out rather than estimated.